Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng Shen

Showing results (511-520 of 515) with videos related to

Pageof 52
Sort By:
You have reached the last page of results.This site can display upto 515 results.
Breast Cancer Research and Treatment|December 13, 2017
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III studyJie Xie, Jun Cao, Jing-Fen Wang, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Nature|February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillanceXin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Cancer Biology & Medicine|February 18, 2026
Expert consensus on the detection and clinical application of tumor mutational burdenZhenying Guo, Chunwei Xu, Shirong Zhang, et al.
Pageof 52

Showing results (511-520 of 515) with videos related to

Sort By:
Pageof 52
You have reached the last page of results.This site can display upto 515 results.
Breast Cancer Research and Treatment|December 13, 2017
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III studyJie Xie, Jun Cao, Jing-Fen Wang, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Nature|February 4, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillanceXin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, et al.
Cancer Biology & Medicine|February 18, 2026
Expert consensus on the detection and clinical application of tumor mutational burdenZhenying Guo, Chunwei Xu, Shirong Zhang, et al.
Pageof 52